Stevens-Johnson syndrome after treatment with rituximab

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1948-1950

  Lowndes, Sarah ^a   Darby, A ^a   Mead, G ^a   Lister, A ^b  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Follicular lymphoma; Rituximab; Side effects; Stevens Johnson syndrome

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CHLORAMBUCIL; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; PERMANGANATE POTASSIUM; PREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BRONCHIOLITIS; CANCER GRADING; CANCER RECURRENCE; CASE REPORT; CLINICAL TRIAL; CONJUNCTIVA DISEASE; DISEASE SEVERITY; ERYTHEMA; FEVER; FOLLICULAR LYMPHOMA; GENITAL ULCER; HEADACHE; HUMAN; LICENSING; MALE; MALNUTRITION; MOUTH ULCER; MOUTHWASH; MUCOSA INFLAMMATION; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PRURITUS; RASH; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; URTICARIA; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

ADULT; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATAL OUTCOME; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME;

EID: 0036929546     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf350     Document Type: Article

References (12)

1. Anderson K, Bates M, Slaughenhoupt B et al. Expression of human B-cell associated antigens in leukaemias and lymphomas: a model of human B-cell differentiation. Blood 1984; 63: 1424-1433.
2. Johnson PWM, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001; 85: 1619-1623.
3. McLaughlin P, Grillo-Lopez AJ et al. Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma. J Clin Oncol 1998; 16: 2825-2833.
4. Coiffier B, Lepage E et al. CHOP chemotherapy plus rituximab compared with CHOP chemotherapy alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002; 346: 235-242.
5. Foran JM, Gupta RK, Cunningham D et al. A UK multicentre phase II study of rituximab in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81-88.
6. Davis TA, White CA, Grillo-Lopez AJ et al. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1851-1857.
7. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
8. Piro LD, White CA, Grillo-Lopez AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
9. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lyphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
10. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
11. Walewski J, Kraszewska E, Mioduszewska O et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicentre study. Med Oncol 2001; 18: 141-148.
12. Weatherall DJ, Leddingham JGG, Warrell DA (eds). Oxford Textbook of Medicine, 3rd edition. Oxford, UK: Oxford University Press 1996.